---
title: "Targeting B Cells in Immune-Mediated Kidney Diseases: KDIGO Controversies Conference Conclusions"
id: "kidney-international-7-targeting-b-cells-in-immune-mediated-kidney-diseases-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference"
canonical_url: "https://medichelpline.com/clinical-feed/kidney-international-7-targeting-b-cells-in-immune-mediated-kidney-diseases-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "Kidney International"
source_url: "https://www.kidney-international.org/article/S0085-2538(26)00226-7/fulltext?rss=yes"
published_at: "2026-03-26T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Targeting B Cells in Immune-Mediated Kidney Diseases: KDIGO Controversies Conference Conclusions
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/kidney-international-7-targeting-b-cells-in-immune-mediated-kidney-diseases-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** Kidney International
- **Source URL:** [Original Journal Publication](https://www.kidney-international.org/article/S0085-2538(26)00226-7/fulltext?rss=yes)
- **Published At:** 2026-03-26T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
KDIGO convened a Controversies Conference in June 2025 to evaluate B cell–targeted strategies for immune-mediated glomerular diseases and to delineate evidence gaps and research needs for implementing these therapies. Available data indicate substantial heterogeneity in the availability, effectiveness, and safety of B cell–targeted interventions across different glomerular conditions. The conference highlighted that results with B cell depletion or modulation are disease-specific rather than universally applicable, with varying implications for clinical outcomes and risk profiles. In IgA nephropathy, rituximab (anti-CD20) has demonstrated limited efficacy based on current evidence. By contrast, approaches targeting B cell–related pathways beyond CD20, including inhibitors of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand), as well as anti-CD38 antibodies, have been associated with reductions in proteinuria and a slower decline in estimated glomerular filtration rate in some studies. However, the overall certainty of these effects remains uncertain due to limited data, heterogeneity of study designs, and incomplete long-term safety information.
## Clinical Analysis & Structured Key Points
Kidney International published a clinical update in Research Highlights on 26 Mar 2026. The item focuses on Targeting B cells in immune-mediated kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Review the original article for the full source wording and details.
## Related Clinical Research

- [Transcriptomic links and candidate biomarkers between ANCA‑GN and IgG4‑RD: ITGAM and CXCL1 identif](https://medichelpline.com/clinical-feed/plos-one-22-transcriptomic-associations-and-biomarkers-in-anca-associated.md)
- [Anti-PLA2R Antibody Levels and Clinical Predictors of Relapse in Primary Membranous Nephropathy](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-anti-pla2r-antibody-levels-and-clinical-risk-factors-for-predicting-relapse-in.md)
- [Telitacicept for Lupus Nephritis: Real‑World Triple‑Cohort Study — Article Content Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-real-world-triple-cohort-study-on-the-effectiveness-and-safety-of.md)
- [Testing frequency explains most SDMT differences between natalizumab and rituximab in Swedish MS r](https://medichelpline.com/clinical-feed/medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between.md)
- [Guideline differences in rheumatoid arthritis-associated interstitial lung disease care](https://medichelpline.com/clinical-feed/pubmed-42888356.md) (DOI: 10.1007/s00296-026-06322-x)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.